AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears
Published . Updated .
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAstrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting statisticall
Directly affected
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAstrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Cong…
Source: Nasdaq Markets
The price since 14 Sep 2026: Astrazeneca (AZN) versus the S&P 500
Since the first closing price after “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears,” Astrazeneca (AZN) is +1.35%. The S&P 500 fund (SPY) is +1.21% over the same days, a +0.14% difference versus the market.
Who reported a Astrazeneca (AZN) trade near this story
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 15 days after publication, inside 30 days. The filing is listed beside the story “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 3 days before publication, inside 30 days. The filing is listed beside the story “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 42 days before publication, inside 60 days. The filing is listed beside the story “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 46 days before publication, inside 60 days. The filing is listed beside the story “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 46 days before publication, inside 60 days. The filing is listed beside the story “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears.”
- Donald J Trump sell GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 59 days before publication, inside 60 days. The filing is listed beside the story “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Astrazeneca (AZN)
Companies tied to this story
- AZN Astrazeneca
Astrazeneca (AZN) is linked, with no stored direction, high confidence in the 14 Sep 2026 story “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears.” Reason on file: The reported development directly names ASTRAZENECA PLC in the headline; GA resolved that company to AZN
- ACHC Acadia Healthcare
In “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 14 Sep 2026 story “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Astrazeneca (AZN)
On 14 Sep 2026, “AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears” is the story that connects Astrazeneca (AZN) to this story.
For Astrazeneca (AZN), the reason on file says The reported development directly names ASTRAZENECA PLC in the headline; GA resolved that company to AZN
Also listed, Acadia Healthcare (ACHC): GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Astrazeneca (AZN) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. AZN traded between 154.83 and 169.73 across 20 sessions. The latest close on file is 164.02.
What the saved facts support for Astrazeneca (AZN)
46 out of 100
“AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.